In recent years, the immunologic origin of melanoma has led to the discovery of antibodies directed against specific targets such as anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (8). This evidence concerns the gene PDCD1 and melanoma.